MARKET NEWS

Calixar Invests in Pipeline of Highly Druggable Membrane Protein Targets & Native Antigens
CeQur Raises $115 Million to Support Commercialization & Scale-Up of Automated Manufacturing for CeQur Simplicity Wearable Insulin Delivery Device
Longeveron Announces Positive Results of Phase 1 Clinical Study of Lomecel-B Cell Therapy 
Akston Biosciences Launches Phase 1/2 Clinical Trial of Second-Generation COVID-19 Vaccine
Catalent Biologics Completes Madison Facility Expansion to Double Clinical & Commercial Drug Substance Capacity
Akouos Receives Orphan Drug & Rare Pediatric Disease Designations 

  FEATURED EDITORIAL

  COMPANY PROFILE


Headquartered in the heart of the Swiss Alps, Datwyler Sealing Solutions is a leading industrial supplier and key player in global markets for system-critical components in healthcare, automotive, and general industry. The healthcare market segment provides state-of-the-art solutions for parenteral drug and medical device packaging. Datwyler Sealing Solutions is a leading manufacturer and a key player in the global healthcare world. Our state-of-the-art solutions for drug packaging and medical devices are built on over 100 years of experience. Click here for more.

Whitepaper Alert: Outsourcing Drug Development & Production: Technology-Driven Drug Delivery Systems for Small Molecules at Losan Pharma
By: Matthias Rischer, PhD, Director Drug Delivery & Innovation Projects, and Jens Morgenthaler, PhD, Managing Director

 

  EXCLUSIVE ONLINE CONTENT

Context Therapeutics & Integral Molecular Enter Collaboration & License Agreement 

Context Therapeutics & Integral Molecular Enter Collaboration & License Agreement 

Context Therapeutics and Integral Molecular recently announced a research collaboration and licensing agreement for the development of an anti-claudin 6 (CLDN6) bispecific monoclonal antibody….

AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for Grade 1 Immune Checkpoint Inhibitor-Associated Colitis

AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for Grade 1 Immune Checkpoint Inhibitor-Associated Colitis

AzurRx BioPharma, Inc. recently announced it has entered into an agreement with PPD, Inc. for its planned Phase 1b/2a clinical trial evaluating proprietary formulations of micronized….

SOTIO Demonstrates Strong Potential of SOT102 (ADC Targeting Claudin 18.2) for Treatment of Solid Tumors in Preclinical Studies

SOTIO Demonstrates Strong Potential of SOT102 (ADC Targeting Claudin 18.2) for Treatment of Solid Tumors in Preclinical Studies

SOTIO recently announced new preclinical data of its antibody-drug conjugate (ADC), SOT102 (formerly SO-N102), for the treatment of solid tumors in a virtual….

Artelo Biosciences Doses First Patient in CAReS Study for the Treatment of Cancer-Related Anorexia & Weight Loss

Artelo Biosciences Doses First Patient in CAReS Study for the Treatment of Cancer-Related Anorexia & Weight Loss

Artelo Biosciences, Inc. recently announced the first patient has been dosed in the company’s Phase 1/2 Cancer Appetite Recovery Study (CAReS) of ART27.13….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

April 28 – Formulation Development
May 5 – Prefilled Syringes